

Data Acquisition

- **Source:** public domains
- **Method:** 1) Entries from search engines, company websites, biotech news feed, social media, and government databases were collected.
2) When an Application Programming Interface (API) tool is available, such as in the case of ClinicalTrials.gov, Python scripts developed in-house were used for automatic querying and retrieval.

Filtering & Validation

- **Filtering:** Entries describing preclinical or clinical development of diagnostic antibodies, polyclonal antibodies, convalescent plasma therapies, immune globulin intravenous (IGIV) therapies, small molecules, and recombinant proteins other than immunoglobulin (Ig), Ig fragments, and Ig fusion proteins were removed from our collection. Studies and clinical trials without explicitly stating COVID-19 or SARS-CoV-2 as their indication or target were also eliminated. Filtering was performed manually unless an API tool was available, in which case, it was performed by the Python scripts mentioned above.
- **Validation:** Validation of each entries we retained in our collection is performed manually, by inspecting and cross-validating using multiple sources if possible.

Data Analysis

- Data analysis was performed, and statistics on key aspects, such as drug targets, format and clinical status were generated using R and Python

Data Visualization

- Interactive table and charts published on our website (chineseantibody.org) were generate using WPDataTable, a commercial plug-in for WordPress. Static table and charts used for this publication were generated using R.

Update & Maintain

- New data are being collected, analyzed, and published on our website on a weekly basis